US3262977A
(en)
*
|
1962-03-10 |
1966-07-26 |
Chinoin Gyogyszer Es Vegyeszet |
N-aralkyl-1, 1-diphenyl-propylamine derivatives
|
NL296693A
(en)
*
|
1962-08-16 |
|
|
|
FR95908E
(en)
*
|
1963-11-09 |
1972-01-31 |
Degussa |
Process for the preparation of novel aminoketones and corresponding secondary alcohols.
|
US3457354A
(en)
*
|
1965-09-21 |
1969-07-22 |
Merck & Co Inc |
Treatment of hypertension with 2-hydroxy (or amino) - 4,5 - dihydroxyphenethylamine derivatives
|
US3895057A
(en)
*
|
1967-10-13 |
1975-07-15 |
Dainippon Pharmaceutical Co |
Aminoalkanols and their pharmaceutically acceptable acid-addition salts, and production thereof
|
US4329367A
(en)
*
|
1974-08-05 |
1982-05-11 |
Ciba-Geigy Corporation |
1-(Aralkoxyphenyl)-2-(bis-arylalkylamino)-alkanes
|
DE2902172C2
(en)
*
|
1979-01-20 |
1984-05-10 |
UOP Inc., 60016 Des Plaines, Ill. |
Process for the preparation of an N, N'-dialkylphenylenediamine
|
WO1983003755A1
(en)
*
|
1982-04-23 |
1983-11-10 |
Caola Kozmetikai És Háztartäsvegyipari Vállalat |
Novel cosmetic compositions containing prenylamine and a process for their preparation
|
NZ215753A
(en)
*
|
1985-04-16 |
1989-10-27 |
Hoffmann La Roche |
Phenethanolamine derivatives and pharmaceutical compositions
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
CN1658903A
(en)
*
|
2001-01-26 |
2005-08-24 |
先灵公司 |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
ATE369851T1
(en)
*
|
2001-01-26 |
2007-09-15 |
Schering Corp |
COMBINATIONS OF BALE ACID SEQUESTRANTS AND STEROL ABSORPTION INHIBITORS FOR THE TREATMENT OF CARDIOVASCULAR INDICATIONS
|
BR0206644A
(en)
*
|
2001-01-26 |
2004-02-25 |
Schering Corp |
Sterol absorption inhibitor (s) combinations with cardiovascular agent (s) for the treatment of vascular conditions
|
US20020183305A1
(en)
*
|
2001-01-26 |
2002-12-05 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
KR100596257B1
(en)
*
|
2001-01-26 |
2006-07-03 |
쉐링 코포레이션 |
A composition comprising sterol absorption inhibitor, and a composition and a therapeutic combinations comprising peroxisome proliferator-activated receptorPPAR activator and sterol absorption inhibitor
|
KR100820983B1
(en)
*
|
2001-01-26 |
2008-04-10 |
쉐링 코포레이션 |
A pharmaceutical composition comprising substituted azetidinone compounds
|
AR038956A1
(en)
*
|
2001-05-25 |
2005-02-02 |
Schering Corp |
USE OF A COMPOUND REGULATING THE PRODUCTION OR LEVELS OF BETA AMILOID PEPTIDES FOR THE MANUFACTURE OF A MEDICINAL PRODUCT TO TREAT ALZHEIMER'S DISEASE AND / OR TO REGULATE SUCH LEVELS OF BETA AMILOID PEPTIDES IN A SUBJECT
|
CA2460340C
(en)
*
|
2001-09-21 |
2011-02-15 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of xanthoma using sterol absorption inhibitors
|
MXPA04002572A
(en)
*
|
2001-09-21 |
2004-05-31 |
Schering Corp |
Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s).
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
AU2003250483A1
(en)
|
2002-08-19 |
2004-03-11 |
Pfizer Products Inc. |
Combination therapy for hyperproliferative diseases
|
AU2003291719A1
(en)
*
|
2002-11-06 |
2004-06-03 |
Schering Corporation |
Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
|
DE602004016123D1
(en)
|
2003-03-07 |
2008-10-09 |
Schering Corp |
SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE FOR THE TREATMENT OF HYPERCHOLESTEROLMIA
|
CA2517573C
(en)
*
|
2003-03-07 |
2011-12-06 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
ATE418551T1
(en)
|
2003-03-07 |
2009-01-15 |
Schering Corp |
SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
EP1796653A2
(en)
*
|
2004-07-26 |
2007-06-20 |
Actelion Pharmaceuticals Ltd. |
Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
EP2351569B1
(en)
|
2005-10-26 |
2012-08-22 |
Asahi Kasei Pharma Corporation |
Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
|
ATE551059T1
(en)
*
|
2005-10-26 |
2012-04-15 |
Asahi Kasei Pharma Corp |
FASUDIL IN COMBINATION WITH BOSENTAN FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
JP5498168B2
(en)
|
2006-12-01 |
2014-05-21 |
ブリストル−マイヤーズ スクイブ カンパニー |
N-((3-Benzyl) -2,2- (bis-phenyl) -propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular disease
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
EA020466B1
(en)
|
2007-06-04 |
2014-11-28 |
Синерджи Фармасьютикалз Инк. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2726917C
(en)
|
2008-06-04 |
2018-06-26 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
CA2730603C
(en)
|
2008-07-16 |
2019-09-24 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
WO2012037665A1
(en)
|
2010-09-24 |
2012-03-29 |
Oral Delivery Technology Ltd. |
Nitric oxide releasing amino acid ester for treatment of pulmonary hypertension and other respiratory conditions
|
EP2970384A1
(en)
|
2013-03-15 |
2016-01-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
JP2016516804A
(en)
|
2013-04-17 |
2016-06-09 |
ファイザー・インク |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
CN113388007A
(en)
|
2013-06-05 |
2021-09-14 |
博士医疗爱尔兰有限公司 |
Ultra-pure agonists of guanylate cyclase C, methods of making and using the same
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
JOP20210193A1
(en)
|
2019-01-18 |
2023-01-30 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|